Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Authors:
  • DMD. Miles
    D. Miles
  • ACA. Chan
    A. Chan
  • GRG. Romieu
    G. Romieu
  • LDL. Y. Dirix
    L. Y. Dirix
  • JCJ. Cortes
    J. Cortes
  • XPX. Pivot
    X. Pivot
  • PTP. Tomczak
    P. Tomczak
  • TTT. Taran
    T. Taran
  • NHN. Harbeck
    N. Harbeck
  • GSG. G. Steger
    G. G. Steger

Abstract
LBA1011 Background: BV (Avastin®), an anti-angiogenic monoclonal antibody that prevents the biologic activity of VEGF, significantly improves overall (OS) and/or progression-free survival (PFS) in four tumour types. In patients with mBC, the phase III study E2100 demonstrated that BV in combination with paclitaxel as 1st-line therapy resulted in superior PFS compared with paclitaxel alone (hazard ratio [HR] = 0.48 as per independent review).The AVADO study investigated the combination of BV and D as first-line therapy in patients with locally recurrent or mBC. Methods: This randomised, double-blind phase III study compared D 100mg/m2 plus PL with D plus either BV 7.5mg/kg or BV 15mg/kg. D was administered q3w for up to 9 cycles. BV/PL was administered q3w until disease progression or unacceptable toxicity. The 1° endpoint was PFS, with 2° endpoints of OS, time to treatment failure, best overall response, duration of response, and safety. Key eligibility criteria were HER2-negative, inoperable locally recu...